Document is current
Any future updates will be listed below
-
Authors
Aluri, Srinivas https://orcid.org/0000-0003-4084-1747
Bachiashvili, Kimo
Budhathoki, Anjali
Jeong, Jong Jin https://orcid.org/0000-0002-3197-409X
Gordon-Mitchell, Shanisha
Chakraborty, Samarpana
Yang, Jung-In
Sahu, Srabani
Pandey, Sanjay https://orcid.org/0000-0003-2948-1816
Sandhu, Micheal
Paul, Mahinder https://orcid.org/0000-0002-0618-8206
Deng, Wenjun
Sanawar, Rahul
Sahu, Plabani https://orcid.org/0009-0002-4178-7949
Kravets, Leah
Aminov, Sarah
Aggarwal, Ritesh
Agarwal, Beamon
Verma, Divij https://orcid.org/0000-0002-2214-9450
Choudhary, Gaurav S.
Bhagat, Tushar D.
Carbajal, Milagros
Zhao, Rongbao
Pradhan, Kith
Maqbool, Shahina https://orcid.org/0000-0002-7873-1378
Kim, Seong-Jin
Steidl, Ulrich G. https://orcid.org/0000-0002-9458-1795
Shastri, Aditi https://orcid.org/0000-0002-5366-8288
Raaijmakers, Marc https://orcid.org/0000-0002-8315-9417
Pellagatti, Andrea
Boultwood, Jacqueline https://orcid.org/0000-0002-4330-2928
Wickrema, Amittha
Verma, Amit https://orcid.org/0000-0001-7592-7693
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (R01CA275007)
Edward P. Evans Foundation
Leukemia and Lymphoma Society
Dempsey Family
- License Information
-
More Information
Article History
Received: 30 July 2025
Accepted: 22 April 2026
First Online: 13 May 2026
Competing interests
: AV has received research funding from Bristol Myers Squibb, Jannsen, MedPacto, Curis, Prelude, Halia and Ryvu. AV has received compensation as a scientific advisor to Stelexis Therapeutics, Halia, Calico and Aurigene, is on the DSMC for Ascentage and has equity ownership in Roshon, Stelexis and clinStreet. US has received research funding from GlaxoSmithKline, Bayer Healthcare, Aileron Therapeutics, and Novartis; has received compensation for consultancy services and for serving on scientific advisory boards from GlaxoSmithKline, Bayer Healthcare, Celgene, Aileron Therapeutics, Stelexis Therapeutics, and Pieris Pharmaceuticals; and has equity ownership in and is serving on the board of directors of Stelexis Therapeutics. AS receives research funding from Kymera and Ryvu Therapeutics. AS is on the advisory boards of Gilead Sciences, Kymera Therapeutics, and Rigel Pharmaceuticals. The remaining authors declare no competing interests.
